Ypsomed Launches New Commercial Product

Ypsomed recently announced it is expanding its mylife product range with the innovative self-injection system mylife DailyDose, which will initially be sold in six European countries. This Swedish innovation ideally compliments the mylife product range, which provides diabetes patients with an extensive selection of products that promote an active and independent lifestyle.

The credit-card sized self-injection system consists of three small syringes, which are prefillable with the diabetic’s daily insulin requirement. Mylife DailyDose can be tucked away comfortably and discretely and used as needed. The transparent case makes it possible to tell at a glance, which dose was already administered.

“Be it sport, travelling, or going out – for diabetics, it is not always practical to carry traditional injection or infusion systems. With mylife DailyDose, a reliable solution is always at hand, which outperforms existing alternatives with regard to practicability and costs. We are delighted to have mylife DailyDose in our mylife product range,” explained Simon Michel, Member of the Executive Board of the Ypsomed group.

The distribution contract with the Swedish manufacturer Insulution AB was sealed recently. Ypsomed will bring mylife DailyDose to the market in Switzerland, Germany, Great Britain, Norway, Austria, and the Netherlands, and other countries will be considered in the future.

The Ypsomed Group is a leading, independent developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with over 25 years of experience. Originated in 2003 from the famous company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disturbances, infertility, and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field.

Ypsomed has established itself with the umbrella brands mylife Diabetescare and YDS Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for treatment of diabetes. The range from YDS reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product line of pen systems and autoinjectors, which can be adapted to customer requirements, contract production in the development and production sectors as well as the assembly of injection systems with medications Ypsomed thus offers demand-orientated product and service solutions to pharmaceutical and biotech companies worldwide. For more information, visit www.ypsomed.com.